In recent clinical trials on various human cancers, including melanoma, targeting an individual pathway, such as the MAPK pathway or the PI3K/Akt pathway, or using a single agent generally failed to show significant clinical responses [9], [15], [32]. This evidence concerns the gene PIK3CA and melanoma.